EGFR and neoplasm: Most of the studies note that, considering advanced inoperable cases, the amount of tumor tissue in bronchoscopy obtained tumor samples is scarce and, in most circumstances, cautiously stored for assessment of the molecular and pathological biomarkers that are necessary for proper selection of the modern systemic treatment (PDL-1 expression, EGFR and ROS mutations, ALK rearrangement etc.).